Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727]

Affiliations

¹ Department of Oncology, Mayo Clinic, Rochester, USA. Electronic address: goetz.matthew@mayo.edu.
² Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
³ Breast Center Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Department of Gynecology, University of Ulm, Ulm, Germany.
⁴ Yonsei Cancer Center, Seoul, Korea.
⁵ Centre Léon Bérard, Lyon, France.
⁶ National Cancer Center, Goyang-si, Korea.
⁷ Institut de Cancérologie de l'Ouest, Angers, France.
⁸ Chang Gung University Medical College, Taipei, Taiwan.
⁹ Hospital Universitario 12 de Octubre, Madrid, Spain.
¹⁰ Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel.
¹¹ Durham Regional Cancer Center, Ontario, Canada.
¹² Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.
¹³ Centre Paul Strauss, INSERM 110, Strasbourg, France.
¹⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
¹⁵ Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, USA.
¹⁶ Hospital Arnau de Vilanova, Valencia, Spain.
¹⁷ Eli Lilly and Company, Indianapolis, USA.
¹⁸ Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
¹⁹ Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Free article

Published Erratum

M P Goetz et al. Ann Oncol. 2025.

Free article

. 2025 Oct 15:S0923-7534(25)00851-8.

doi: 10.1016/j.annonc.2025.07.002. Online ahead of print.

¹ Department of Oncology, Mayo Clinic, Rochester, USA. Electronic address: goetz.matthew@mayo.edu.
² Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
³ Breast Center Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Department of Gynecology, University of Ulm, Ulm, Germany.
⁴ Yonsei Cancer Center, Seoul, Korea.
⁵ Centre Léon Bérard, Lyon, France.
⁶ National Cancer Center, Goyang-si, Korea.
⁷ Institut de Cancérologie de l'Ouest, Angers, France.
⁸ Chang Gung University Medical College, Taipei, Taiwan.
⁹ Hospital Universitario 12 de Octubre, Madrid, Spain.
¹⁰ Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel.
¹¹ Durham Regional Cancer Center, Ontario, Canada.
¹² Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.
¹³ Centre Paul Strauss, INSERM 110, Strasbourg, France.
¹⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
¹⁵ Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, USA.
¹⁶ Hospital Arnau de Vilanova, Valencia, Spain.
¹⁷ Eli Lilly and Company, Indianapolis, USA.
¹⁸ Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
¹⁹ Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.

No abstract available

Erratum for

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O'Shaughnessy J, Pivot X, Tolaney SM, Hurvitz SA, Llombart-Cussac A, André V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD. Goetz MP, et al. Ann Oncol. 2024 Aug;35(8):718-727. doi: 10.1016/j.annonc.2024.04.013. Epub 2024 May 8. Ann Oncol. 2024. PMID: 38729566 Clinical Trial.